Oncology

The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
Top articles of the week from Specialty Pharmacy Times.
[[thumbnail_alt_text]]
Men with breast cancer had higher mortality than women regardless of cancer type, treatment, and access to care.
[[thumbnail_alt_text]]
A new method of targeted radiation therapy sends alpha-emitting particles directly to stroma cells in pancreatic cancer tissue.
[[thumbnail_alt_text]]
Pharmacy Times® will be on site at the 61st American Society of Hematology Annual Meeting and Exposition.
 
[[thumbnail_alt_text]]
Psychological factors such as anxiety and depression can directly influence a patient’s experience with cancer-related pain.
[[thumbnail_alt_text]]
Expert physicians and pharmacists consider the frontline treatment approach, with special consideration of the roleo f frontline neoadjuvant chemotherapy in treating individuals with ovarian cancer.
[[thumbnail_alt_text]]
Specialty Pharmacy Times will be on-site in San Antonio, TX, for the 2019 San Antonio Breast Cancer Symposium, taking place December 10 to 14, 2019.

 
[[thumbnail_alt_text]]
It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.
[[thumbnail_alt_text]]
Trastuzumab-dkst (Ogivri, Mylan, Biocon), a biosimilar to trastuzumab (Herceptin, Genentech Inc.), has been launched in the US, according to an announcement from Mylan N.V. and Biocon Ltd. It is the first biosimilar approved by the FDA and recommended by the FDA Oncologic Drugs Advisory Committee.
[[thumbnail_alt_text]]
Key opinion leaders provide an overview of ovarian cancer and consider the associated risk factors.
[[thumbnail_alt_text]]
Under a new international collaboration, the FDA has granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia.
 
[[thumbnail_alt_text]]
Durvalumab (Imfinzi, AstraZeneca) and tremelimumab plus chemotherapy improved progression-free survival in first-line stage 4 non-small cell lung cancer.